O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 13, 08:34 PM

In our exclusive interview, O’Dea discussed the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.